Because p53 plays a role in epigenetic repression of L1 (39) and a recent study demonstrated that L1 expression in cancer correlates with p53 mutations (40), it is reasonable to expect a correlation between p53 inactivation in the tumor and the development of an anti-L1 antibody response. The gene discussed is TP53; the disease is cancer.